GenScript Biotech Corporation Voluntary Announcement: Legend Biotech’s Phase 1 CAR-T Therapy Data to be Presented at EHA 2026
Key Highlights for Investors
- Legend Biotech Corporation, an associate of GenScript Biotech Corporation, will present promising preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, at the European Hematology Association (EHA) 2026 Congress.
- The late-breaking oral presentation will focus on initial Phase 1 clinical results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).
- The EHA 2026 Congress will take place from June 11 to June 14, 2026 in Stockholm, Sweden.
- Legend Biotech has issued a press release and filed a Form 6-K with the U.S. SEC, providing details of the preliminary clinical data.
Potential Impact for Shareholders
- Positive Clinical Results: The announcement of promising initial Phase 1 data could signal a breakthrough in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma, a significant unmet medical need. This may positively influence sentiment towards both Legend Biotech and GenScript Biotech.
- Market Sensitivity: The news is potentially price-sensitive, as successful CAR-T therapies have historically driven significant share price movements in biotech companies. Investors should closely monitor further updates and detailed data during the EHA Congress.
- Regulatory and Commercial Implications: Early data, if confirmed in further trials, could pave the way for regulatory approvals and commercialization opportunities, impacting future revenue streams and valuation.
- Risk Advisory: Shareholders and investors are strongly advised to exercise caution and be aware of investment risks. The company has specifically highlighted that they should pay attention to potential risks when dealing in GenScript Biotech securities.
Further Details
Legend Biotech’s LB2501 is an investigational in vivo CAR-T therapy targeting both CD19 and CD20 antigens, designed for patients with difficult-to-treat B-cell non-Hodgkin lymphoma. The therapy is being evaluated in a Phase 1 trial, and the initial data will be showcased in a late-breaking session at a major international conference, underscoring its potential significance in the hematology and oncology fields.
Additional information, including the full SEC filing and press release, is available on the SEC’s website and Legend Biotech’s investor relations page. Investors should review these resources for more comprehensive details.
The board of GenScript Biotech Corporation, led by Chairman and Executive Director Robin Meng, reiterates the importance of careful consideration and risk awareness for investors in light of this announcement.
Board and Management
- Executive Directors: Mr. Jiange Meng (Robin Meng), Dr. Fangliang Zhang (Frank Zhang), Dr. Li Zhu, Ms. Ye Wang (Sally Wang)
- Independent Non-Executive Directors: Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (Andy Cheung), Mr. Jiuan Pan (Ethan Pan), Dr. John Quelch, Dr. Ross Grossman, Dr. Chenyang Shi (Victor Shi)
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult financial professionals before making investment decisions. GenScript Biotech Corporation has advised shareholders to pay attention to investment risks and exercise caution in trading.
基因合成生物科技公司自願公告：Legend Biotech的LB2501 CAR-T療法第一期數據將於EHA 2026公佈
投資者重點摘要
- Legend Biotech Corporation，基因合成生物科技公司的聯營公司，將在歐洲血液學協會（EHA）2026大會上公佈其研發中的體內CD19/CD20雙靶點CAR-T細胞療法LB2501的初步臨床數據。
- 該突破性口頭報告將聚焦於復發／難治型B細胞非霍奇金淋巴瘤（R/R B-NHL）患者的第一期臨床結果。
- EHA 2026大會將於2026年6月11日至14日在瑞典斯德哥爾摩舉行。
- Legend Biotech已向美國證券交易委員會（SEC）提交Form 6-K並發佈新聞稿，公佈初步臨床數據詳情。
對股東的潛在影響
- 積極臨床結果：初步第一期數據的公佈可能代表復發／難治型B細胞非霍奇金淋巴瘤治療上的突破，這將正面影響Legend Biotech及基因合成生物科技的市場情緒。
- 市場敏感度：此消息具潛在價格敏感性，成功的CAR-T療法過往曾推動生物科技公司股價大幅上升。投資者應密切留意EHA大會期間公布的進一步數據。
- 監管及商業機遇：若初步數據在後續試驗中得到確認，將有機會推動監管批准及商業化，影響未來收入及估值。
- 風險提示：公司特別提醒股東及投資者注意投資風險，交易基因合成生物科技證券時需謹慎。
更多詳情
Legend Biotech的LB2501屬於體內CAR-T療法，雙靶點CD19及CD20，針對難治性B細胞非霍奇金淋巴瘤患者。療法現正進行第一期臨床試驗，初步數據將於國際會議上公佈，顯示其在血液腫瘤學領域的重大潛力。
有關更多資料，包括完整SEC申報及新聞稿，可於SEC網站及Legend Biotech投資者關係頁面查閱。投資者應查閱相關資源以了解更多詳情。
基因合成生物科技公司董事會，由主席兼執行董事Robin Meng領導，再次強調此公告對投資者慎重考慮及風險意識的重要性。
董事及管理層
- 執行董事：孟建革（Robin Meng）、張方亮（Frank Zhang）、朱力、王燁（Sally Wang）
- 獨立非執行董事：Alphonse Galdes、楊耀良（Andy Cheung）、潘久安（Ethan Pan）、John Quelch、Ross Grossman、施晨陽（Victor Shi）
免責聲明
本文章僅供資料參考，不構成任何投資建議。投資者應自行研究並諮詢專業財務顧問後作出投資決策。基因合成生物科技公司提示股東注意投資風險，交易時需謹慎。
